Serotonin receptors, social phobia and panic disorder

References

• Ballenger J.C., Burrows G.D., DuPont, Jr., Lesser I.M., Noyes, Jr., Pecknold J.D., Rifkin A., Swinson R.P. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Archives of General Psychiatry 1988; 45: 413–422
   PubMedGoogle Scholar
• Barrett J.E., Witkin J.M., Mansbach R.S., Skolnick P., Weismann B.A. Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. Journal of Pharmacology and Experimental Therapeutics 1986; 238: 1009–1013
   Google Scholar
• Bressa MariniS., Gregori S.C. Serotonin S2 receptors blockage and generalized anxiety disorders. International Journal of Clinical Pharmacology Research 1987; 7(2)111–119
   PubMedGoogle Scholar
• Broekkamp C.L.E., Berendsen H.H.G., Jenck F., Van Delft A.M.L. Animal models for anxiety and response to serotonergic drugs. Psychopathology 1989; 22(suppl. 1)2–12
   PubMedGoogle Scholar
• Chouinard G., Annable L., Fontaine R., et al. Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study. Psychopharmacology 1982; 77: 229–233
   PubMed Web of Science ®Google Scholar
• Colpaert F.C., Meert T.F., Niemegeers C.J.E., Janssen P.A.J. Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rats. Psychopharmacology 1985; 86: 45–54
   Google Scholar
• Coplan J., Gorman J., Klein D. Serotonin Related Functions in Panic-Anxiety: A Critical Overview. Neuropsychopharmacology 1992; 6(3)189–200
   Google Scholar
• Csernansky J., Sheline Y. Abnormalities of Serotonin Metabolism and Nonpsychotic Psychiatric Disorders. Annals of Clinical Psychiatry 1993; 5: 275–282
   Google Scholar
• Davidson J.R.T., Tupler L.A., Potts N.L.S. Treatment of Social Phobia With Benzodiazepines. Journal of Clinical Psychiatry 1994; 55(6)28–32, suppl
   Google Scholar
• De Keyser J., Vauquelin G., de Backer J.P., de Vos H., Wilczak N. What intracranial tissues in humans contain sumatriptan-sensitive serotonin 5-HT1-type receptors?. Neuroscience Letters 1993; 164(1–2)63–66
   Google Scholar
• den Boer J.A., Westenberg H.G. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 1990; 102(1)85–94
   Google Scholar
• Eison A., Eison M. Serotonergic Mechanisms in Anxiety. Progressive Neuro-Psychopharmacological, & Biological Psychiatry 1994; 18: 47–62
   Google Scholar
• Emmanouil D.E., Quock R.M. Effects of benzodiazepine agonist, inverse agonist and antagonist drugs in the mouse staircase test. Psychopharmacotogy 1990; 102: 95–97
   Google Scholar
• Evans L., Kenardy J., Schneider P., Hary H. Effect of a selective serotonin uptake inhibitors in agoraphobia with panic attacks. A double-blind comparison of zimelidine, imipramine and placebo. Acta Psychiatrica Scandinavica 1986; 73(1)49–53
   Google Scholar
• Freeman D. The Current Impact of Neuroscience on Psychotropic Drug Discovery and Development. Psychopharmacological Bulletin 1992; 28(1)3–9
   Google Scholar
• Gardner C.R. Recent development in 5-HT related pharmacology of animal models of anxiety. Pharmacology and Biochemistry and Behavior 1986; 24: 1479–1485
   Google Scholar
• Geller I., Blum K. The effects of 5-HTP on parachbrophenylalanine (PCPA) attenuation of ‘conflict’ behavior in the rat. European Journal of Pharmacology 1970; 9: 319–324
   Web of Science ®Google Scholar
• Gleeson, Barrett J.E. 5-HT1A agonist effects on punished responding of squirrel monkeys. Pharmacology, Biochemistry and Behavior 1990; 37: 335–337
   Google Scholar
• Gorman J.M., Liebowitz M.R., Fyer A.J., Goetz D., Campeas R.B., Fyer M.R., Daview S.O., Klein D.F. An open trial of fluoxetine in the treatment of panic attacks (published erratum appears in Journal of Clinical Psychopharmacology). Journal of Clinical Psychopharmacology 1988; 7(5)329–332
   Google Scholar
• Hoehn-Saric R., McLeod D.R., Hipsley P.A. Effect of Fluvoxamine on Panic Disorder. Journal of Clinical Psychopharmacology 1993; 13: 321–326
   PubMed Web of Science ®Google Scholar
• Humble M., Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. International Clinical Psychopharmacology 1992, Suppl. 5: 21–39
   Google Scholar
• Jones B.J., Costall B., Domeney A.M., Kelly M.E., Naylor R.J., Oakley N.R., Tyers M.B. The potential anxiolytic activity of GR38032f, a 5-HT3 receptor antagonist. British Journal of Pharmacology 1988; 93: 985–993
   PubMed Web of Science ®Google Scholar
• Judd L. Social Phobia: A Clinical Overview. Journal of Clinical Psychiatry 1994; 55(6)5–9, suppl
   Google Scholar
• Kennett G.A. 5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology 1992; 107: 379–384
   Web of Science ®Google Scholar
• Kessler R., NcGonagle D., Zhao S., Nelson C., Hughes M., Eshleman S., Wittchen H., Kendler K. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Klein D. Delineation of two drug-responsive anxiety syndromes. Psychopharmacology 1964; 5: 397–408
   PubMed Web of Science ®Google Scholar
• Klein D. Importance of psychiatric diagnosis in prediction of clinical drug effects. Archives of General Psychiatry 1967; 16: 118–126
   PubMed Web of Science ®Google Scholar
• Laurent J.P., Margold M., Hunkel V., Haeflely W. Reduction by two benzodiazepines and pentobarbitone of the multiunit activity in substantia nigra, hippocampus, nucleus locus coeruleus and dorsal raphe nucleus of encephale isole' rats. Neuropharmacology 1983; 22: 501–512
   PubMed Web of Science ®Google Scholar
• Lesch K., Wolozin B., Murphy D., Riederer P. Primary Structure of the Human Platelet Serotonin Uptake Site: Identity with the Brain Serotonin Transporter. Journal of Neurochemistry 1993; 60(6)2319–2322
   Google Scholar
• Liebowitz M.R. Imipramine in the Treatment of Panic Disorder and Its Complications. Psychiatric Clinics of North America 1985; 8: 37–47
   Google Scholar
• Liebowitz M.R., Schneier F.R., Hollander E., Welkowitz L.A., Saoud J.B., Feerick J., Campeas R., Fallon B.A., Street L., Gitow A. Treatment of Social Phobia With Drugs Other Than Benzodiazepines. Journal of Clinical Psychiatry 1991; 52(11)10–15, suppl
   Google Scholar
• Liebowitz M.R., Schneier F., Campeas R., Hollander E., Hatterer J., Fyer A., Gorman J., Papp L., Daview S., Gully R., Klein D.F. Phenelzine vs Atenolol in Social Phobia; A Placebo-Controlled Comparison. Archives of General Psychiatry 1992; 49: 290–300
   PubMed Web of Science ®Google Scholar
• Lydiard R.B., Laraia M.T., Howell E.F., Ballenger J.C. Alprazolam in the Treatment of Social Phobia. Journal of Clinical Psychiatry 1988; 49: 17–19
   PubMed Web of Science ®Google Scholar
• McBride P.A., Mann J.J., McEwen B., Biegon A. Serotonin binding sites on human platelets. Presented at the 139th APA 1986; 55: 132, Abstract
   Google Scholar
• Maisonnette S., Morato S., Brandao M. Role of Resocialization and of 5-HT1A Receptor Activation on the Anxiogenic Effects Induced by Isolation in the Elevated Plus-Maze Test. Physiology, & Behavior 1993; 54: 753–758
   PubMed Web of Science ®Google Scholar
• Mansbach R.S., Harrod C., Hoffman S.M., Nader M.A., Lei Z., Witkin J.M., Barrett J.E. Behavioral studies with anxiolytic drugs. v. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding. Journal of Pharmacology and Experimental Therapeutics 1988; 246: 119–120
   Google Scholar
• Marsden C.A. The pharmacology of new anxiolytics acting on 5-HT neurones. Postgraduate Medical Journal 1990; 66(suppl. 2)52–56
   Google Scholar
• Marshall R.D., Schneier F.R., Fallon B.A., Feerick J., Liebowttz M.R. Medication Therapy for Social Phobia. Journal of Clinical Psychiatry 1994; 55(6)33–37, suppl
   Google Scholar
• Murphy D. Neuropsychiatry Disorders and the Multiple Human Brain Serotonin Receptor Subtypes and Subsystems. Neuropsychopharmacology 1990; 3(56)457–471
   Google Scholar
• Norman T.R., Sartor D.M., Judd F.K., Burrows G.D., Gregory M.S., McIntyre I.M. Platelet serotonin uptake and 3H-imipramine binding in panic disorder. Journal of Affective Disorders 1989a; 17: 77–81
   PubMed Web of Science ®Google Scholar
• Norman T., Judd F., Burrows G., McIntyre I. Platelet Serotonin Uptake in Panic Disorder Patients: A Replication Study. Psychiatry Research 1989a; 30: 63–68
   PubMed Web of Science ®Google Scholar
• Norman T., Judd F., Gregory M., James R., Kimber N., McIntyre I., Burrows G. Platelet serotonin uptake in panic disorder. Journal of Affective Disorders 1986; 11: 69–72
   PubMed Web of Science ®Google Scholar
• Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscientific Methods 1985; 14: 149–167
   PubMed Web of Science ®Google Scholar
• Piercy M.F., Hoffman W.E. 2-Deoxyglucose autoradiography pinpoints and serotonin neuron depression as a common mode of action for 5-HT1A and benzodiazepine-type anxiolytics. Cell Biology to Pharmacology, & Therapy 1989; 90
   Google Scholar
• Pohl R., Balon R., Yeragani V.K., Genshon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989; 22(Suppl 1)60–67
   Google Scholar
• Regier D.A., Myers J.K., Kramer M., Robins L.N., Blazer D.G., Hough R.L., Eaton W.W., Locke B.Z. The NIMH Epidemiologic Catchment Area Program. Archives of General Psychiatry 1984; 41: 934–941
   PubMed Web of Science ®Google Scholar
• Regier D.A., Boyd J.H., Burke J.D., Rae D.S., Myers J.K., Kramer M., Robins L.N., George L.K., Karno M., Locke B.Z. One-month prevalence of mental disorders in the United States. Archives of General Psychiatry 1988; 45: 977–986
   PubMed Web of Science ®Google Scholar
• Schneier F.R., Liebowttz M.R., Daview S.O., Fairbanks J., Hollander E., Campeas R., Klein D.F. Fluoxetine in panic disorder. Journal of Clinical Psychopharmacology 1990; 10(2)119–121
   Google Scholar
• Schreiber R., de Vry J. 5-HT1A Receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action?. Progressive Neuro-Psychopharmacological, & Biological Psychiatry 1993; 17: 87–104
   PubMed Web of Science ®Google Scholar
• Sheehan D.V., Raj A.B., Harnett-Sheehan K., Soto S., Knapp E.L. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder a double-blind placebo-controlled study. Acta Psychiatrica Scandinavica.
   Google Scholar
• Sheehan D.V., Claycomb J.B., Surman O.S. The relative efficacy of phenelzine, imipramine, alprazolam, and placebo in the treatment of panic attacks and agoraphobia. Presented at meeting on Biology of Panic Disorders. 1983
   Google Scholar
• Sheehan D.V. Monoamine Oxidase Inhibitors and Alprazolam in the Treatment of Panic Disorder and Agoraphobia. Psychiatric Clinics of North America 1985; 8: 49–61
   Google Scholar
• Sheehan D.V., Raj A.B., Sheehan K.H., Soto S. Is buspirone effective for panic disorder?. Journal of Clinical Psychopharmacology 1990; 10(1)3–11
   PubMed Web of Science ®Google Scholar
• Sheehan D., Claycomb J., Surman O., et al. Comparison of phenelzine, imipramine, alprazolam, and placebo in the treatment of panic attacks and agoraphobia. Presented at the American Psychiatric Association Annual Meeting, Los Angeles. 1984
   Google Scholar
• Sheehan D., Raj B., Trehan R., Knapp E. Serotonin in panic disorder and social phobia. International Clinics in Psychopharmacology 1993; 8(2)63–77
   Google Scholar
• Soubric P. Reconciling the role of central serotonin neurons in human and animal behavior. Behavioural Brain Science 1986; 9: 319–364
   Google Scholar
• Stahl S.M., Gastpar M., Keppel Hesselink J.M., Traber J. Serotonin 1A receptors in Depression and Anxiety. Raven Press, Ltd., New York 1992
   Google Scholar
• Stefanski R., Palejko W., Kostowski W., Plaznik A. The Comparison of Benzodiazepine Derivatives and Serotonergic Agonists and Antagonists in Two Animal Models of Anxiety. Neuropharmacology 1992; 31: 1251–1258
   PubMed Web of Science ®Google Scholar
• Tancer M.E., Golder R.N. Monoamine neurotransmitter function in social phobia. Travel Award Poster, American College of Neuropsychopharmacology 1992
   Google Scholar
• Targum S.D., Marshall L.E. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Research 1989; 28: 295–306
   PubMedGoogle Scholar
• Tye N.C., Iversen S.D., Green A.R. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 1979; 18: 689–695
   PubMed Web of Science ®Google Scholar
• Van Ameringen M., Mancini C., Streiner D. Sertraline in social phobia. Journal of Affective Disorders 1994; 141–145
   Google Scholar
• Vardermaelen C.P., Matheson G.K., Wilderman R.C., Patterson L.A. Inhibition of serotonergic dorsal raphe neurons by systemic and iontopheretic administration of buspirone, a non-benzodiazepine anxiolytic drug. European Journal of Pharmacology 1986; 129: 123–130
   Google Scholar
• Versiani M., Nardi A.E., Mundim F.D., Alves A.B., Lebowitz M.R., Amrein R. Pharmacotherapy of Social Phobia; A Controlled Study with Moclobemide and Phenelzine. British Journal of Psychiatry 1992; 161: 353–360
   PubMed Web of Science ®Google Scholar
• Westenberger H.G., den Boer J.A. Serotonin-influencing drugs in the treatment of panic disorder. Psychopathology 1989; 22(suppl 1)68–77
   Google Scholar